Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological disorder that affects the peripheral nerves, leading to progressive weakness and sensory loss. Often considered the chronic counterpart of Guillain-Barré Syndrome (GBS), CIDP occurs when the immune system mistakenly attacks the myelin sheath, the protective covering of the nerves. Early diagnosis and treatment are essential to prevent long-term nerve damage and improve quality of life for those affected. Understanding the symptoms and available treatment options can help individuals manage this condition more effectively.
Common Symptoms and Treatment Approaches
CIDP symptoms often develop gradually over weeks or months and may include muscle weakness, numbness, tingling, and loss of reflexes, primarily in the arms and legs. Some individuals experience difficulty walking, fatigue, and coordination issues. Treatment typically focuses on reducing inflammation and immune system activity. First-line therapies include intravenous immunoglobulin (IVIG), corticosteroids, and plasma exchange (plasmapheresis). In more severe or resistant cases, immunosuppressive drugs or biologic therapies may be recommended. Early intervention and ongoing management can help slow disease progression and improve mobility and function.